Skip to content
Study details
Enrolling now

18F-rhPSMA PET-CT Imaging Performance in Prostate Cancer Patients

City of Hope Medical Center
NCT IDNCT06580015ClinicalTrials.gov data as of Apr 2026
Target enrollment

20

Study length

about 1.8 years

Ages

21+

Sex

Male only

Locations

1 site in CA

What this study is about

This trial is testing the performance of 18F-rhPSMA PET-CT imaging in men with prostate cancer. The goal is to improve the quality of images captured on a specific system used for radiation therapy planning and delivery.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Flotufolastat F-18 Gallium
  • 2.Medical Device Usage and Evaluation
  • 3.Undergo Computed Tomography
  • +1 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

flotufolastat (18F)

Endpoints

Primary: Comparison of imaging performance of the [18F]-rhPSMA positron emission tomography (PET)-computed tomography (CT) on the X1 RefleXion Medical Radiotherapy System (RMRS)

Procedures

imaging